M's Science and Eisai Sign Option Agreement for Sigma Agonist SA4503

14-Mar-2008

M's Science Corporation and Eisai Co., Ltd. announced that the companies entered into an option agreement for SA4503, a novel sigma agonist which is being developed by M's Science in Europe for the treatment of depression and post-stroke therapy.

Under the terms of the agreement, M's Science will grant Eisai the following rights in exchange for a certain payment: the first review right for evaluating the results of the two Phase II studies of the compound currently ongoing in Europe for the above two indications and the first negotiation right regarding the development and marketing of the compound.

SA4503 is a novel, small molecule, selective sigma receptor agonist with activity in preclinical models of CNS diseases to enhance neuroregeneration/maturation. Four human Phase I studies including one PET study with SA4503 have been completed in the Netherlands, and the safety profile of this compound in healthy individuals as well as its brain pharmacokinetics, and receptor binding/occupancy have been established. Currently, two Phase II studies are being conducted in Europe for the treatment of central nervous system disorders (major depression and post-stroke recovery).

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances